| 证券代码 | FCSC.O |
| 证券名称 | Fibrocell Science Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2014-08-29 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Fibrocell Science, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 405 Eagleview Boulevard, Exton, Pennsylvania, USA |
| 成立日期 | 1995 |
| 董事会主席 | Douglas J. Swirsky |
| 公司属地 | United States 美国 |
| 公司网址 | www.fibrocell.com |
| 电话 | +1 (484) 713-6000 |
| 传真 | - |
| 公司简介 | Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Its approach to personalized biologics is distinctive and the foundation of its personalized biologics platform is its proprietary autologous fibroblast technology. Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. The company targets the underlying cause of disease by using fibroblast cells from a patient's skin to create localized therapies with genetic modification that are compatible with the unique biology of the patient (i.e., autologous). |